Dorkhan Mozhgan, Dencker Magnus, Frid Anders
1Department of Clinical Sciences, Division of Diabetes & Endocrinology, Lund University, Malmö University Hospital, Malmö, Sweden.
Cardiovasc Diabetol. 2008 Apr 30;7:12. doi: 10.1186/1475-2840-7-12.
There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.
近年来，人们对噻唑烷二酮类药物（TZDs）可能产生的心脏副作用极为关注。我们报告一例60岁男性病例，该患者在使用吡格列酮治疗六个月期间出现了严重的二尖瓣反流，同时实验室检查显示有液体潴留迹象。停药六个月后超声心动图显示二尖瓣反流减轻，实验室参数也恢复正常。值得注意的是，吡格列酮治疗六个月可诱发严重的瓣膜功能障碍，且这种功能障碍是可逆的，这突出了在患者接受TZDs治疗时仔细监测的重要性。
